PHARMACYCLICS Aktie

25,80 EUR -1,1118%

Zu Ihrem Onlinebroker

kaufen verkaufen

PHARMACYCLICS Aktienkurs : 08:08 ( 15 Min. verzögert)
25,80 € Letzter Kurs	-1,11% Veränderung	26,09 € Vortag	25,80 € Eröffnungskurs

mehr Informationen

Hoch/Tief		Volumen		Geldkurs	Briefkurs
25,80 - 25,80 Tag	26,09 - 4,59 52 Wochen	0 Tag	5 Ø 52 Wochen	0,0000000 0 Stücke	0,0000000 0 Stücke

PHARMACYCLICS Aktienkurs

Wollen Sie wissen, wie es mit dieser Aktie weitergeht?
Wir informieren Sie kostenlos.

Erhalten Sie außerdem Expertenanalysen von:
Gevestor Täglich und John Gossens Daily DAX

27.05.

Biotechnology Stocks To Watch Ahead Of ASCO 2012: Part 4

Pharmacyclics, Inc (PCYC): Pharmacyclics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing small-molecule drugs for the treatment of cancer and immune...
23.05.

How High Can Pharmacyclics Fly?

By Sean Williams , The Motley Fool Shares of Pharmacyclics (NAS: PCYC) hit a 52-week high yesterday. Let's take a look at how it got there and whether clear skies...

22.05.

DSW, Pharmacyclics, Other Stocks Hit 52-Week Highs Tuesday

The share price of Pharmacyclics (PCYC) increased today, reaching and then surpassing its previous 52-week high of $31.31. In spite of its performance and peak...
22.05.

Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the ...

SUNNYVALE, Calif., May 22, 2012 /PRNewswire via COMTEX/ -- Pharmacyclics, Inc. (NASDAQ:PCYC) today announced that clinical abstracts on Bruton's Tyrosine Kinase inhibitor, ibrutinib (formerly, PCI-32765) have been selected for oral...
21.05.

Pharmacyclics (NASDAQ:PCYC) Reports Clinical Abstracts at ASCO – PCYC, SPPI ...

Pharmacyclics, Inc (NASDAQ:PCYC) reported on Friday that clinical abstracts on Bruton's Tyrosine Kinase inhibitor, ibrutinib have been selected for oral presentations at the 48th Annual summit of…